INSM Key Stats
- Short Interest Expands By 13.2% For INSM The Street Nov 27
- Piper Jaffray Starts Insmed (INSM) at Overweight Street Insider Nov 26
- INSMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation Nov 26
- Use Options For A Chance To Buy INSM At A 48% Discount Nov 13
- H.C. Wainwright Starts Insmed (INSM) at Buy Street Insider Nov 11
- Coverage initiated on Insmed by HC Wainwright Nov 10
- Insmed Incorporated Management Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 5
- Insmed Incorporated Earnings Call scheduled for 8:30 am ET today Nov 5
- Insmed Reports Third Quarter 2013 Financial Results noodls Nov 5
- Insmed, Inc. Discusses Q3 2013 Results (Webcast) Seeking Alpha Nov 5
INSM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Insmed is up 135.4% over the last year vs S&P 500 Total Return up 30.43%, Durata Therapeutics up 32.20%, and Repros Therapeutics up 18.42%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for INSM
Pro Report PDF for INSM
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download INSM Pro Report PDF
Pro Strategies Featuring INSM
Did Insmed make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Insmed, Inc. is a development-stage biopharmaceutical company. The Company develops inhaled treatments for serious lung infections.